Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
企業コードNAUT
会社名Nautilus Biotechnology Inc
上場日Aug 07, 2020
最高経営責任者「CEO」Mr. Sujal Patel
従業員数155
証券種類Ordinary Share
決算期末Aug 07
本社所在地2701 Eastlake Ave East
都市SEATTLE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号98102
電話番号12063332001
ウェブサイトhttps://www.nautilus.bio/
企業コードNAUT
上場日Aug 07, 2020
最高経営責任者「CEO」Mr. Sujal Patel
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし